Retatrutide represents breakthrough peptide therapy as a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. This randomized controlled trial evaluated retatrutide clinical trial results in 324 adults with type 2 diabetes and obesity through evidence-based medicine protocols. Clinical trial updates show participants receiving retatrutide achieved significant weight reduction (mean 22.8% from baseline) and improved glycemic control compared to placebo, with generally well-tolerated gastrointestinal side effects documented in pharmaceutical research.